Compare · head to head
Exelixis vs Puma Biotechnology
Exelixis ranks higher overall — 360 rank 96 vs 79.
Exelixis leads on Value (65 vs 59) and Sentiment (46 vs 38). The two are close on Quality, Growth and Safety.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | USA | USA |
| Sector | Health Care | Health Care |
| Industry | Biotechnology | Biotechnology |
| Size | Large | Small |
| ISIN | US30161Q1040 | US74587V1070 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 96 | 79 |
| Value | 65 | 59 |
| Quality | 82 | 78 |
| Growth | 49 | 45 |
| Safety | 64 | 60 |
| Sentiment | 46 | 38 |
| Quality details | ||
| Profitability | 96 | 96 |
| Cash Truth | 68 | 59 |
Exelixis vs Coherus OncologyExelixis vs Janux TherapeuticsExelixis vs IDEAYA BiosciencesExelixis vs Rigel PharmaceuticalsAdd a third stock →
Full analyses: Exelixis · Puma Biotechnology
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100